ZEUS System (Zio Watch)

by iRhythm Technologies  · Based in United States → — Shaping the future of heart monitoring and empowering better health for all.
Cardiology Family Medicine Internal Medicine

Contact vendor
Regulatory Status Disclosed

Overview

The ZEUS System (Zio Watch) by iRhythm Technologies is an FDA-cleared, AI-powered wearable solution designed for long-term continuous cardiac monitoring. It combines a patient-centric wearable biosensor, the Zio Watch, with the ZEUS (Zio ECG Utilization Software) System, which is an artificial intelligence algorithm. This integrated system processes and analyzes electrocardiogram (ECG) and photoplethysmogram (PPG) data to detect and report on the presence and burden of Atrial Fibrillation (AFib) over an extended monitoring period, typically up to 14 days.

The iRhythm monitoring service, which includes the Zio Watch and ZEUS System, aims to provide clinicians with accurate, clinically actionable insights to aid in the diagnosis of cardiac arrhythmias. Data collected by the Zio Watch is analyzed by an FDA-cleared, deep-learned algorithm and then curated and verified by Qualified Cardiac Technicians to generate comprehensive end-of-wear reports. Physicians can interpret these reports and manage patients through the ZioSuite® portal and a dedicated provider mobile app, while patients are supported by the MyZio® app for symptom logging and educational content. The system is designed to be comfortable and convenient for patients, promoting high compliance, and integrates seamlessly with Electronic Health Records (EHRs) to streamline clinical workflows.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Wearable biosensor (Zio Watch) for continuous ECG and PPG data collection
  • AI-powered algorithm (ZEUS System) for advanced arrhythmia detection and analysis
  • Long-term continuous monitoring for up to 14 days
  • Detects and characterizes Atrial Fibrillation (AFib) burden
  • Cloud-based data analytics and processing
  • Clinically actionable reports with high physician agreement (99%)
  • ZioSuiteu00ae portal and provider mobile app for report interpretation and patient management
  • MyZiou00ae patient app for digital symptom logging, educational content, and reminders
  • Patient-centric design (small, comfortable, breathable, waterproof)
  • Seamless Electronic Health Record (EHR) integration

Use Cases

  • Long-term continuous monitoring for Atrial Fibrillation (AFib)
  • Detection and diagnosis of various cardiac arrhythmias
  • Providing clinically actionable insights for physicians
  • Remote patient monitoring and management
  • Reducing the need for repeat cardiac testing
  • Early detection and prevention of cardiac disease

What Physicians Need to Know

ECG/EKG Analysis Capability
The ZEUS System processes and analyzes electrocardiogram (ECG) and photoplethysmography (PPG) based data. It utilizes an AI-based algorithm (AFib Context Engine - ACE) to detect and characterize Atrial Fibrillation (AFib) over time. The system also employs an AI-based ECG Analysis Software (ECGDL) to generate initial ECG-based cardiac information. The deep-learned algorithm is clinically proven to be as accurate as cardiologists, with data curated and verified by Qualified Cardiac Technicians.
Arrhythmia Detection Accuracy
The Zio Watch with ZEUS System has received FDA 510(k) clearance for monitoring AFib. The AFib Context Engine (ACE) algorithm within the ZEUS System demonstrated interval-level sensitivity of 93.6% and specificity of 99.1% for AFib detection. The PPG-derived AFib burden estimate from the Zio Watch was found to be an accurate measure when compared to the Zio XT reference. The broader iRhythm monitoring service, which includes Zio devices, is associated with a high diagnostic yield for various arrhythmias, detecting up to 13 types of arrhythmia classes.
Cardiac Monitoring Integration
The Zio Watch with the ZEUS System is an integrated, prescription-based solution. It integrates with the ZioSuite web portal and mobile app, allowing healthcare professionals to manage workflows, register patients, order monitors, and view/interpret reports. Seamless Electronic Health Record (EHR) integration is available, including through the Epic Aura network, which facilitates direct transmission of Zio orders and results. The MyZio patient app supports patients with digital symptom logging, educational content, and reminders.
Real-Time Alert Capability
The Zio Watch with ZEUS System is designed to detect AFib and characterize its burden over time, with preliminary reports sent to the patient's clinician for review. While the Zio AT patch (part of the broader iRhythm service) offers real-time or near real-time alerts for higher-risk patients and can transmit asymptomatic arrhythmias during wear, the Zio Watch primarily focuses on post-monitoring analysis and reporting to aid in diagnosis, rather than providing real-time alerts to the physician during the wear period.
Physician Tip

Leverage the Zio Watch's extended monitoring capabilities (up to 14 days) for a higher diagnostic yield, particularly for transient or paroxysmal atrial fibrillation, which might be missed by shorter-term monitoring. Utilize the ZioSuite portal and EHR integration for efficient patient management, streamlined ordering, and comprehensive report interpretation. Remember that the ZEUS System provides AI-analyzed and technician-verified reports to aid in diagnosis and management of AFib, and it is indicated for adult patients (22 years or older) susceptible to or diagnosed with AFib, not for critical care patients.

The Zio Watch with ZEUS System is designed for seamless integration into clinical workflows. It offers robust EHR integration, including a direct connection with Epic Aura, which streamlines the ordering process, patient registration, and electronic delivery of detailed reports. The ZioSuite web portal and mobile application serve as central hubs for healthcare professionals to manage patients and access clinical data. Additionally, the MyZio patient app enhances patient engagement by providing tools for symptom logging and educational resources.

Details

Category Cardiology AI, Wearables & Remote Monitoring (RPM)
Pricing Contact vendor — N/A
DeploymentCloud-based system with a wearable device
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

The ZEUS System (Zio Watch) received FDA 510(k) clearance (K213409) on July 19, 2022. It is intended to process and analyze ECG and PPG based data to detect and report on the presence of Atrial Fibrillation (AF) over the monitoring period, providing ECG information for diagnosis and contextual information for AF. It is indicated for adult patients 22 years or older who are susceptible to developing or have been diagnosed with AF, and is not intended for use on critical care patients.

Integrations
EHR Not specified
Specialties Cardiology, Family Medicine, Internal Medicine

What the Web Says

The ZEUS System (Zio Watch) is an FDA-cleared, prescription-based wearable and software system designed for long-term continuous monitoring and detection of Atrial Fibrillation (AFib) and other cardiac arrhythmias. It aims to provide clinical-grade data to physicians, aiding in diagnosis and intervention. The Zio Watch utilizes continuous photoplethysmography (PPG) and AI-based algorithms to detect AFib and estimate its burden over time.

Overall: Positive

Strengths

  • Clinical-grade, long-term continuous monitoring for AFib and other arrhythmias.
  • FDA-cleared device and AI-powered software for accurate data analysis.
  • Provides comprehensive, curated reports to clinicians, improving diagnostic yield and reducing the need for repeat testing.
  • Patient-centric design with a small, comfortable, water-resistant adhesive patch, leading to high patient compliance.
  • Automated alerts to clinicians when abnormalities are detected, allowing for earlier intervention.
  • MyZio app for digital symptom logging and educational content.

Limitations

  • Some users report skin irritation, itching, or rash from the adhesive.
  • Device may become loose or fall off, especially with sweat or physical activity.
  • Lack of real-time feedback to the patient.
  • Concerns about the device hitting transmission limits, potentially leading to missed data for high-risk patients.
  • Some users on Reddit found consumer smartwatches (like Apple Watch) to be superior in detecting AFib in specific instances.
  • Not yet commercially available at the time of some reviews (2022-2023).

Based on reviews from: Reddit, Good e-Reader, accessdata.fda.gov, DAIC, Medical Product Outsourcing, Cardiac Rhythm News, YouTube, iRhythm, PubMed, Oxford Academic, Capterra, Apple App Store, MedGrade

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate ZEUS System (Zio Watch)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Clinical Trials Arena
US FDA grants 510(k) clearance for iRhythm Technologies' ZEUS system
The US FDA granted 510(k) clearance for iRhythm Technologies' clinically integrated Zio ECG Utilization Software (ZEUS) System, developed in collaboration with Verily. The ZEUS System will serve as the AI algorithm and solution component for the Zio Watch, a wearable device designed for long-term continuous monitoring of atrial fibrillation (AFib).
2022-07
X-ray Interpreter
ZEUS System (Zio Watch) | FDA Radiology AI Device - X-ray Interpreter
The ZEUS System (Zio Watch) is a prescription-based wearable device and software system that utilizes AI to analyze cardiac signals from ECG and PPG sensors to detect and report atrial fibrillation. It provides clinicians with detailed reports to aid in diagnosing and managing AF in adult patients.
2022-07
BioWorld
US FDA clears IRhythm-Verily watch for use in afib diagnosis | BioWorld
The U.S. FDA cleared the Zio Watch, developed by Verily and iRhythm Technologies, as the first clinical-grade watch for characterizing atrial fibrillation. The device leverages iRhythm's ZEUS system, combining wearable biosensing with cloud-based data analytics and AI for cardiac arrhythmia diagnosis.
2022-08
accessdata.fda.gov
510(k) Premarket Notification - ZEUS System (Zio Watch)
The FDA's 510(k) summary for the ZEUS System (Zio Watch) details its substantial equivalence to predicate devices and its intended use to process and analyze ECG and PPG data for atrial fibrillation detection and reporting. The system uses machine learning techniques for both ECGDL and AF Context Engine algorithms.
2022-07
RhythmScience
Best Wearable Heart Monitors for Cardiology in 2026 - RhythmScience
iRhythm's ZEUS System (Zio Watch) is listed among FDA-authorized wearable sensor-based digital health technology devices for cardiovascular use. The article highlights the Zio XT patch's continuous ECG monitoring with high sensitivity for arrhythmia detection and 99% physician agreement on end-of-wear reports.
2026-02
IQVIA Institute for Human Data Science
Digital Health Trends 2024 Implications for Research and Patient Care
The IQVIA Institute's 'Digital Health Trends 2024' report mentions iRhythm Technologies' ZEUS System and Zio Watch as examples of digital diagnostics and remote patient monitoring tools. It discusses how these AI-informed digital platforms are helping providers improve outcomes for patients with chronic diseases.
2023-10
Thesis/Dissertation
ANALYZING ADVERSE EVENTS OF FDA APPROVED AI-ENABLED MEDICAL DEVICES FOR RISK-AWARE DEVELOPMENT A THESIS SUBMITTED TO THE GRADUAT
A thesis analyzing adverse events of FDA-approved AI-enabled medical devices includes the ZEUS System (Zio Watch) as a device for long-term, non-invasive monitoring for atrial fibrillation and other arrhythmias. It highlights the use of deep learning to analyze continuous PPG signals for AF detection and burden estimation.
unknown
Physician AI Tools
Us2.ca vs ZEUS System (Zio Watch) - Physician AI Tools
This comparison article positions the ZEUS System (Zio Watch) as an FDA-cleared, AI-powered wearable for long-term continuous cardiac monitoring, specifically designed to detect and characterize Atrial Fibrillation and other cardiac arrhythmias. It emphasizes its suitability for outpatient settings to provide actionable insights into arrhythmia burden.
unknown

Videos

Product demos, reviews, and walkthroughs for ZEUS System (Zio Watch).

Loading videos...

View all on YouTube

Frequently Asked Questions

The ZEUS System's AI analyzes continuous ECG and PPG data from the Zio Watch to detect and characterize atrial fibrillation (AFib) over time, generating preliminary reports for clinician review. This aims to provide actionable insights to aid in diagnosis and support timely clinical intervention.
The ZEUS System for the Zio Watch received FDA 510(k) clearance for monitoring cardiac arrhythmia, specifically AFib. iRhythm, the developer, is committed to HIPAA compliance, employing robust data security protocols to protect patient health information when the data is integrated into medical records.
The Zio Watch, powered by the ZEUS System, offers continuous, long-term, clinical-grade monitoring with AI-driven arrhythmia detection, unlike traditional Holter monitors. It is a prescription-based diagnostic device, providing comprehensive analysis and reports to clinicians, which distinguishes it from consumer smartwatches primarily used for screening.
The Zio monitoring service is covered by many major commercial insurance providers and Medicare nationwide. Patients may incur out-of-pocket expenses such as co-pays, deductibles, or co-insurance, but iRhythm offers patient assistance programs and direct billing to insurance for the technical component.
While the ZEUS System's AI demonstrates high sensitivity and specificity for AFib detection, like all AI, it may still generate false positives or negatives, especially in complex cases or due to signal artifacts. Physicians must use their clinical judgment and not rely solely on AI output for diagnosis and treatment decisions.
iRhythm provides educational resources and a dedicated learning platform, iRhythm Academy, offering expert-guided tutorials on Zio products and services, as well as content on arrhythmia detection and ambulatory cardiac monitoring. This support aims to help healthcare professionals effectively integrate the system's insights into their practice.

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

More from iRhythm Technologies

ZEUS System
iRhythm Technologies
Cardiology AI
The ZEUS System by iRhythm Technologies is an AI-powered software that analyzes ECG data from wearable biosensors for long-term continuous cardiac monitoring, aiding in the detection and characterization of arrhythmias like Atrial Fibrillation.
Zio AT ECG Monitoring System
iRhythm Technologies, Inc.
Cardiology AI
The Zio AT ECG Monitoring System by iRhythm Technologies is an FDA-cleared, wearable mobile cardiac telemetry (MCT) service offering continuous, AI-powered ECG monitoring for long-term arrhythmia detection and comprehensive reporting.
Zio ECG Utilization Software (ZEUS) System
iRhythm Technologies
Cardiology AI
The Zio ECG Utilization Software (ZEUS) System by iRhythm Technologies is an AI-powered, cloud-based platform that analyzes continuous ECG data from wearable Zio monitors to aid physicians in the diagnosis and management of cardiac arrhythmias.
Zio XT ECG Monitoring System
iRhythm Technologies
Cardiology AI
The Zio XT ECG Monitoring System by iRhythm Technologies offers a wearable, single-lead ECG biosensor for up to 14 days of continuous cardiac monitoring, utilizing FDA-cleared AI and expert review for accurate arrhythmia detection and diagnosis.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18

Investors who backed ZEUS System (Zio Watch)

Funded through the company that built this tool.

AI Tool Finder
AI-powered search. Results may not be comprehensive.